Disease-modifying therapies and symptomatic management for primary biliary cholangitis

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the destruction of bile ducts.
• Significant gaps in patient care and treatment strategies for PBC have been identified in recent publications.
• Current management often involves addressing symptoms alongside disease-modifying therapies.

Purpose of the Study:

• To review current literature on licensed first- and second-line therapies for PBC.
• To evaluate therapeutic options for symptomatic management of PBC, including pruritus and fatigue.
• To assess the potential of emerging disease-modifying therapies.

Main Methods:

• Literature review of scientific publications on primary biliary cholangitis therapies.
• Analysis of safety and efficacy data for approved and investigational treatments.
• Evaluation of symptomatic management strategies based on existing evidence.

Main Results:

• Ursodeoxycholic acid is the recommended first-line therapy; obeticholic acid is a second-line option, both with proven safety and efficacy.
• Cholestyramine is a first-line treatment for pruritus, but evidence is limited and side effects are common.
• No licensed therapy exists for PBC-related fatigue; addressing underlying causes is advised. Fibrates and budesonide require further study.

Conclusions:

• Combined consideration of disease-modifying and symptomatic therapies is crucial for effective PBC patient management.
• While emerging therapies show promise, further randomized controlled trials are needed to confirm their long-term efficacy.
• Addressing unmet needs in symptomatic treatment, particularly for fatigue, remains a priority in PBC care.